Andrei Shustov
Directeur Technique/Scientifique/R&D chez CELLECTAR BIOSCIENCES, INC.
Fortune : 166 212 $ au 30/04/2024
Postes actifs de Andrei Shustov
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 15/02/2023 | - |
Historique de carrière de Andrei Shustov
Anciens postes connus de Andrei Shustov
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | - | - |
Formation de Andrei Shustov
| S. I. Georgievsky's Medical Academy | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Russie | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Bourse
- Insiders
- Andrei Shustov
- Expérience